Design and synthesis of naturally-inspired SARS-CoV-2 inhibitors

被引:3
|
作者
Hassan, Haitham [1 ]
Chiavaralli, Jeanne [2 ]
Hassan, Afnan [3 ,4 ]
Bedda, Loay [3 ,4 ]
Krischuns, Tim [5 ]
Chen, Kuang-Yu [5 ]
Li, Alice Shi Ming [6 ]
Delpal, Adrien [7 ]
Decroly, Etienne [7 ]
Vedadi, Masoud [6 ,8 ]
Naffakh, Nadia [5 ]
Agou, Fabrice [2 ]
Mallart, Sergio [1 ]
Arafa, Reem K. [3 ,4 ]
Arimondo, Paola B. [1 ]
机构
[1] Univ Paris Cite, Inst Pasteur, Dept Struct Biol & Chem, CNRS,UMR 3523,Chem4Life,Epigenet Chem Biol, F-75015 Paris, France
[2] Univ Paris Cite, Inst Pasteur, Ctr Technol Resources & Res C2RT, CNRS,UMR 3523,Chem4Life,Chemogen & Biol Screening, F-75015 Paris, France
[3] Drug Design & Discovery Lab, Zewail City Sci & Technol, Cairo 12578, Egypt
[4] Univ Sci & Technol, Biomed Sci Program, Zewail City Sci & Technol, Cairo 12578, Egypt
[5] Univ Paris Cite, Inst Pasteur, Unit Biol ARN & Virus Influenza, CNRS,UMR3569, F-75015 Paris, France
[6] Univ Toronto, Dept Pharmacol & Toxicol, Toronto, ON, Canada
[7] Marseille Univ, CNRS, UMR7257, AFMB Aix, Marseille, France
[8] QBI COVID 19 Res Grp QCRG, San Francisco, CA USA
来源
RSC MEDICINAL CHEMISTRY | 2023年 / 14卷 / 03期
关键词
D O I
10.1039/d2md00149g
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A naturally inspired chemical library of 25 molecules was synthesised guided by 3-D dimensionality and natural product likeness factors to explore a new chemical space. The synthesised chemical library, consisting of fused-bridged dodecahydro-2a,6-epoxyazepino[3,4,5-c,d]indole skeletons, followed lead likeness factors in terms of molecular weight, C-sp(3) fraction and Clog P. Screening of the 25 compounds against lung cells infected with SARS-CoV-2 led to the identification of 2 hits. Although the chemical library showed cytotoxicity, the two hits (3b, 9e) showed the highest antiviral activity (EC50 values of 3.7 and 1.4 mu M, respectively) with an acceptable cytotoxicity difference. Computational analysis based on docking and molecular dynamics simulations against main protein targets in SARS-CoV-2 (main protease M-pro, nucleocapsid phosphoprotein, non-structural protein nsp10-nsp16 complex and RBD/ACE2 complex) were performed. The computational analysis proposed the possible binding targets to be either M-pro or the nsp10-nsp16 complex. Biological assays were performed to confirm this proposition. A cell-based assay for M-pro protease activity using a reverse-nanoluciferase (Rev-Nluc) reporter confirmed that 3b targets M-pro. These results open the way towards further hit-to-lead optimisations.
引用
收藏
页码:507 / 519
页数:13
相关论文
共 50 条
  • [41] Naturally occurring anthraquinones as potential inhibitors of SARS-CoV-2 main protease: an integrated computational study
    Sourav Das
    Anirudh Singh
    Sintu Kumar Samanta
    Atanu Singha Roy
    Biologia, 2022, 77 : 1121 - 1134
  • [42] Design, synthesis and in silico screening of benzoxazole-thiazolidinone hybrids as potential inhibitors of SARS-CoV-2 proteases
    Cheerala, Vijay Sai Krishna
    Ghanta, Prasanth
    Neelakantan, Sundaresan Chittor
    RSC ADVANCES, 2021, 11 (62) : 39328 - 39342
  • [43] Synthetic Coumarin Derivatives as SARS-CoV-2 Major Protease Inhibitors: Design, Synthesis, Bioevaluation and Molecular Docking
    Mohamed, Nada M.
    Eltelbany, Rania F. A.
    CHEMISTRYSELECT, 2021, 6 (47): : 13616 - 13626
  • [44] Design, synthesis, and molecular dynamics simulation studies of quinoline derivatives as protease inhibitors against SARS-CoV-2
    Singh, Vishal K.
    Chaurasia, Himani
    Kumari, Priyanka
    Som, Anup
    Mishra, Richa
    Srivastava, Ritika
    Naaz, Farha
    Singh, Anuradha
    Singh, Ramendra K.
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2022, 40 (21): : 10519 - 10542
  • [45] Allosteric inhibitors of the main protease of SARS-CoV-2
    Samrat, Subodh Kumar
    Xu, Jimin
    Xie, Xuping
    Gianti, Eleonora
    Chen, Haiying
    Zou, Jing
    Pattis, Jason G.
    Elokely, Khaled
    Lee, Hyun
    Li, Zhong
    Klein, Michael L.
    Shi, Pei-Yong
    Zhou, Jia
    Li, Hongmin
    ANTIVIRAL RESEARCH, 2022, 205
  • [46] Advances in the Development of SARS-CoV-2 Mpro Inhibitors
    Agost-Beltran, Laura
    de la Hoz-Rodriguez, Sergio
    Bou-Iserte, Lledo
    Rodriguez, Santiago
    Fernandez-de-la-Pradilla, Adrian
    Gonzalez, Florenci V.
    MOLECULES, 2022, 27 (08):
  • [47] Discovery of PLpro and Mpro Inhibitors for SARS-CoV-2
    Puhl, Ana C.
    Godoy, Andre S.
    Noske, Gabriela D.
    Nakamura, Aline M.
    Gawriljuk, Victor O.
    Fernandes, Rafaela S.
    Oliva, Glaucius
    Ekins, Sean
    ACS OMEGA, 2023, 8 (25): : 22603 - 22612
  • [48] Potential inhibitors of SARS-CoV-2: recent advances
    Soufi, Ghazaleh Jamalipour
    Iravani, Siavash
    JOURNAL OF DRUG TARGETING, 2021, 29 (04) : 349 - 364
  • [49] Dihydroorotate dehydrogenase inhibitors in SARS-CoV-2 infection
    Coelho, Ana R.
    Oliveira, Paulo J.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2020, 50 (10)
  • [50] Developing inhibitors of the SARS-CoV-2 main protease
    Seitz, Christian
    Markota, Vedran
    Sztain-Pedone, Terra
    Esler, Morgan
    Moghadasi, Arad
    Kennelly, Samantha
    Demir, Ozlem
    Aihara, Hideki
    Harki, Daniel A.
    Harris, Reuben
    McCammon, J. Andrew
    Amaro, Rommie E.
    BIOPHYSICAL JOURNAL, 2022, 121 (03) : 192A - 192A